Melasma: Visible-Light Photoprotection Is the Base No Supplement or Laser Can Replace

Summary

Melasma is driven by visible light as well as ultraviolet — not UV alone — layered on hormonal triggers (pregnancy, combined oral contraceptives), which is why strict broad-spectrum photoprotection that actually blocks visible light (a tinted, iron-oxide sunscreen) is the non-negotiable base without which every topical and procedure underperforms; on top of that base the proven adjuncts are topicals (hydroquinone, tretinoin, azelaic acid, and the fixed triple-combination cream) used on a maintenance footing, procedures are cautious-and-conservative because aggressive lasers can rebound and dar

Why Moderate

Moderate because the entry's load-bearing claims rest on real but limited trial evidence: the visible-light photoprotection base comes from small, single-centre RCTs plus a relapse-prevention trial; the strongest topical (the triple combination) has two blinded RCTs but they are short (8 weeks) and manufacturer-run; azelaic acid rests on older blinded comparative trials; the laser-rebound caution is a systematic review of heterogeneous, often uncontrolled studies; and the tranexamic-acid efficacy is meta-analytic but for a prescription drug with contraindications. That is a coherent, trial-anchored evidence base — but small, short, or industry-linked in places, which is Moderate, not Strong.

NOT Strong because no single load-bearing claim rests on a large, long-duration, independent RCT; the photoprotection trials are small and single-centre, and the best topical evidence is short and manufacturer-run.

NOT Emerging for the headline, because the spine — visible light drives melasma so photoprotection must cover it, the proven topicals genuinely reduce MASI, aggression rebounds, and the supplement market is unsupported — is backed by multiple blinded trials and meta-analyses, not a handful of suggestive reports.

The per-lever split (read this, not just the headline):
• Visible-light photoprotection as the base: Moderate (small single-centre RCT + relapse-prevention trial; strong for the lever specifically).
• Triple-combination cream: Moderate (two blinded RCTs, short and manufacturer-run).
• Azelaic acid ≈ hydroquinone: Moderate (older blinded comparative RCTs).
• Hydroquinone ochronosis harm: Moderate / Emerging (case-series and pharmacovigilance).
• Aggressive lasers rebound: Moderate (systematic review, safety caveat).
• Oral supplement / glutathione / detox market: Experimental / unsupported.
• Low-dose oral tranexamic acid efficacy: Moderate (RCTs + meta-analyses), but classed as a prescription drug with contraindications, not a supplement.

Practical takeaway

The framing to hold: melasma is a chronic-relapsing, light- and hormone-driven pigment condition. The levers genuinely help, but the honest verb is control, not cure — and photoprotection that covers visible light is the base you cannot skip. No over-the-counter pill or aggressive laser is a shortcut past it.

Build the base first — visible-light photoprotection (non-negotiable).
• Use a tinted / iron-oxide broad-spectrum sunscreen daily, reapplied — the tint is what blocks the visible light that drives melasma, so a clear UV-only sunscreen is not enough here. (General sun behaviour and mineral-versus-chemical choice are owned by sunscreen_mineral_vs_chemical_and_sensible_sun; the light biology is owned by artificial_light_vs_sunlight.)
• Treat this as the maintenance layer that continues indefinitely, not a treatment you stop when the pigment fades.

Add the proven topicals as adjuncts on the base (control-not-cure footing).
• Triple-combination cream (tretinoin + hydroquinone + a mild steroid) is the best-supported topical for a supervised, time-limited course — strongest short-term efficacy, but on a maintenance footing, not a permanent regimen.
• Hydroquinone works but is a time-limited course, not a forever-cream (see the ochronosis risk below); use under supervision and taper.
• Azelaic acid 20% is a legitimate non-hydroquinone alternative — useful where hydroquinone is restricted or avoided (including pregnancy).

Keep procedures cautious and conservative — never as a shortcut.
• If procedures are used at all, they should be low-energy and conservative (e.g. cautious chemical peels, low-energy lasers) and only after the photoprotection-and-topical base is in place. Aggressive, high-energy lasers can rebound and darken melasma, especially in darker skin.

Ignore the supplement / detox market.
• Oral glutathione, IV "whitening" drips, herbal lightening capsules, lemon-juice and "detox" regimens are unsupported to weak. They are not a treatment; do not spend on them expecting melasma to clear.

The one systemic option is a prescription drug — via a clinician.
• Low-dose oral tranexamic acid genuinely reduces melasma, but it is a prescription anti-fibrinolytic, not a supplement. It requires medical assessment because it is contraindicated in thrombotic risk and interacts with the combined oral contraceptives that can trigger melasma. Ask a clinician; do not self-source.

Set the expectation.
• Melasma is chronic-relapsing. The goal is control and slowed relapse with an ongoing photoprotection base and periodic topical maintenance — not a one-and-done cure.

Evidence detail

Why This Entry Exists

Melasma is misadvised in two opposite directions at once, and the market noise is loud enough to bury the one lever that actually holds everything else up. The first error is the sunscreen error: people are told "wear SPF" as if any UV sunscreen were enough, when melasma is also driven by visible light, so a standard clear chemical sunscreen leaves the dominant trigger uncovered and the pigment keeps coming back. The second error is the pill error: a multi-billion-dollar, largely unregulated skin-lightening market sells oral glutathione, IV "whitening" drips, herbal capsules and lemon-juice "detox" regimens as if a supplement could fix melasma. None of that has the evidence to stand as a treatment.

So this entry holds both truths together. The evidence-based levers genuinely help — strict visible-light photoprotection first, then hydroquinone, tretinoin, azelaic acid, and the triple combination — AND melasma is a chronic-relapsing condition that is easily worsened. Aggressive lasers can rebound it. Hydroquinone has real limits and a genuine misuse harm (exogenous ochronosis after years of overuse). The supplement and detox market is unsupported. The message a person with melasma needs is "these levers work, on a control-not-cure footing, and photoprotection including visible light is the base you cannot skip — and no over-the-counter pill or aggressive laser is a shortcut past it."

What bad advice this protects against, in all directions:
• "Just wear sunscreen" → a plain UV sunscreen misses visible light, which independently drives melasma; the lever is a tinted / iron-oxide (visible-light-blocking) sunscreen, not just any SPF.
• "A whitening supplement / glutathione pill / IV drip will fix it" → the oral-supplement, glutathione and detox market is unsupported to weak; systematic reviews grade the evidence low-quality. No OTC pill clears melasma.
• "Lemon juice / a detox regimen lightens pigment" → no controlled evidence at all; acidic home remedies can irritate and worsen post-inflammatory pigment.
• "Just laser it off" → aggressive/high-energy lasers can rebound and darken melasma, especially in darker skin; procedures must be cautious, low-energy and conservative, not the first move.
• "Hydroquinone is a forever cream" → prolonged misuse (years) risks exogenous ochronosis, a paradoxical blue-black staining that is hard to reverse; HQ is a time-limited course, not a permanent one.
• "Hydroquinone is dangerous, avoid it entirely" → the opposite over-correction; used as a supervised, time-limited course it is one of the best-supported topicals. The risk is misuse, not use.
• "No pill works, full stop" → over-reaches: low-dose ORAL tranexamic acid (a prescription anti-fibrinolytic, not a supplement) genuinely reduces melasma — but it has thrombotic contraindications and interacts with the OCPs that trigger the condition.
• "Get the topicals right and you're cured" → melasma is chronic-relapsing; without ongoing photoprotection and maintenance it comes back. The verb is control, not cure.

This entry owns the visible-light-photoprotection-is-the-base rule and the control-not-cure hierarchy (photoprotection → proven topicals → cautious procedures; supplements are noise) for melasma. It defers general skincare to evidence_based_minimal_skincare, sun behaviour to sunscreen_mineral_vs_chemical_and_sensible_sun, and the biology of visible versus ultraviolet light to artificial_light_vs_sunlight. It states those boundaries and routes there rather than re-arguing them.

Evidence

Organised by lever, with the tier signal inline. The headline is Moderate — the photoprotection base and the topicals have real trial support, but the trials are mostly small, short, or manufacturer-run, so read the tiers, not just the thesis.

Photoprotection has to cover VISIBLE light, not just UV — this is the mechanistic and clinical core (Moderate).

1. Adding visible-light protection to a UV sunscreen measurably improves melasma. In an 8-week double-blind randomised trial of 68 women, an iron-oxide tinted broad-spectrum sunscreen combined with 4% hydroquinone produced about 15% greater MASI improvement at 8 weeks than a UV-only sunscreen plus the same hydroquinone. The tinted (visible-light-blocking) arm won on a hard pigmentation endpoint, which is the finding that reframes the whole condition: visible light, not ultraviolet alone, drives melasma. (Castanedo-Cazares JP, et al. Photodermatol Photoimmunol Photomed 2014, double-blind RCT, n=68, iron-oxide tinted vs UV-only sunscreen + 4% HQ. Moderate — small single-centre RCT, hard MASI endpoint, biologically plausible and consistent with tinted-sunscreen review literature. Leans strong for the photoprotection lever specifically.)

2. Visible-light-covering photoprotection also prevents relapse, not just active disease. A prospective randomised comparative trial found that a sunscreen combining UV protection with short-wavelength visible-light protection reduced melasma relapse versus a UV-only sunscreen during high-sun periods. This substantiates photoprotection as the maintenance base of a chronic-relapsing condition, not merely a treatment adjunct. (Boukari F, et al. "Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light." J Am Acad Dermatol 2015, prospective randomised comparative trial. Moderate — relapse-prevention design directly supports the control-not-cure, photoprotection-is-the-base framing.)

The best-supported topical is the fixed triple combination — but the evidence is short and manufacturer-run (Moderate).

3. The triple-combination cream is the strongest single topical. The fixed combination of tretinoin 0.05% + hydroquinone 4% + fluocinolone acetonide 0.01% was tested in two 8-week multicentre investigator-blind RCTs, in which roughly 77% of patients reached a melasma severity score of 0 to 1 at week 8, beating each of the corresponding dual combinations. It was FDA-approved as Tri-Luma (Galderma) in 2002. This is the firmest topical signal in the file — but it is short (8 weeks) in a chronic-relapsing disease and manufacturer-run, so read it as short-term efficacy, not durable remission. (Taylor SC, et al. "Efficacy and safety of a new triple-combination agent for the treatment of facial melasma." Cutis 2003 (PMID 12889718). Moderate — two multicentre blinded RCTs with a standardised endpoint, but short duration and industry-funded.)

Azelaic acid is a legitimate hydroquinone alternative, useful where HQ is restricted or in pregnancy (Moderate).

4. Azelaic acid 20% is broadly comparable to hydroquinone 4%. Head-to-head double-blind trials found 20% azelaic acid broadly comparable to 4% hydroquinone, with hydroquinone acting faster; a 24-week double-blind trial (n=329) reported about 65% good-to-excellent results for azelaic acid. This matters where hydroquinone is restricted or avoided (notably pregnancy), giving a proven non-HQ option. (Verallo-Rowell VM, et al. double-blind azelaic acid vs hydroquinone trial, Acta Derm Venereol Suppl 1989 (PMID 3073279); Balina LM, Graupe K, 24-week trial, Int J Dermatol 1991 (PMID 1816137). Moderate — older but blinded comparative RCTs, consistent direction across trials.)

Hydroquinone's downside is concrete, not theoretical — which is why it is a course, not a forever-cream (Moderate for the harm).

5. Exogenous ochronosis follows prolonged hydroquinone misuse. Exogenous ochronosis — a paradoxical blue-black pigmentation that is hard to reverse — is associated with prolonged, high-concentration, poorly-sun-protected use of lightening creams; in case characterisations ochronosis appeared only after years of lightening-cream use, concentrated on cheeks, forehead and temples. This is the honest risk anchor and the reason the entry keeps hydroquinone as a time-limited, supervised course rather than an indefinite one. (Exogenous ochronosis case-series / review literature, e.g. Charlin R, et al. Int J Dermatol 2008 (a four-case report) and skin-of-colour case characterisations; classic review Levin CY, Maibach HI, 2001. Moderate/Emerging for the harm claim — case-series and pharmacovigilance evidence, not RCT, but it is the honest risk anchor.)

Aggressive procedures rebound — the counterweight to the "just laser it off" pitch (Moderate, as a safety caveat).

6. Lasers can worsen melasma, especially in darker skin. Recurrence and even worsening of melasma during or after laser treatment is not uncommon, and even low-fluence Q-switched Nd:YAG can induce hyperpigmentation through inflammation, particularly in darker (Fitzpatrick IV to VI) skin. This justifies cautious, low-energy, conservative procedural use only — never aggression as a shortcut. (Low-fluence Q-switched Nd:YAG for melasma: systematic review, PMC9323185, documenting recurrence/rebound and inflammation-driven worsening. Moderate — systematic review of heterogeneous, often uncontrolled laser studies; the signal is a safety/relapse caveat, not an efficacy endorsement.)

The oral-supplement / glutathione / detox market is unsupported to weak (Experimental / unsupported).

7. Oral glutathione and herbal "lightening" adjuncts have weak, low-quality evidence. Systematic reviews of oral glutathione and of herbal/oral adjuncts (including Polypodium leucotomos) grade the overall evidence quality as weak or incomplete, with at most a modest adjunct effect and no basis for a stand-alone "lightening pill." Lemon-juice and "detox" claims have no controlled evidence at all, and the small trials in this space are publication-bias-prone. (Sarkar R, et al. "Glutathione as a skin-lightening agent and in melasma: a systematic review." Int J Dermatol 2025 (evidence graded weak); herbal-adjunct RCT meta-analysis, PMC8668325. Experimental / unsupported for the market claim — reviews explicitly flag low study quality and publication bias. Funding note: skin-lightening is a multi-billion-dollar, largely unregulated market; glutathione IV drips and whitening supplements are sold direct-to-consumer with no efficacy gate — cui bono strongly favours over-claiming here.)

The one systemic exception is a prescription drug, not a supplement — and it carries real contraindications (Moderate for efficacy).

8. Low-dose oral tranexamic acid genuinely reduces melasma — but it is an anti-fibrinolytic, not a supplement. Low-dose oral tranexamic acid (commonly 250 mg twice daily, roughly one-sixth of the hemostatic dose) reduces melasma, with multiple RCTs and meta-analyses reporting a consistent, clinically meaningful MASI reduction. It is a prescription anti-fibrinolytic. Meta-analyses report no thromboembolic events at these low doses, BUT it remains contraindicated in people at thrombotic risk and interacts with the combined oral contraceptives that are themselves a melasma trigger. This is the nuance the title must not overstate: a systemic agent works, and it is not an over-the-counter pill or supplement. (Feng X, et al. updated meta-analysis of RCTs, J Clin Pharm Ther 2021; Bala HR, et al. "Oral Tranexamic Acid for the Treatment of Melasma: A Review," Dermatologic Surgery 2018;44(6):814-825; typical dose 250 mg twice daily. Moderate for efficacy — multiple RCTs and meta-analyses — but it belongs under "prescription drug with real contraindications," not "safe supplement." Funding note: off-label cheap generic; little commercial push, so if anything its real signal is under-marketed relative to the glutathione hype.)

Mechanism

This entry owns the photoprotection-and-hierarchy logic, not the full biology of light or of hormonal signalling. The physics of visible versus ultraviolet light is deferred to artificial_light_vs_sunlight; the endocrinology of the combined oral contraceptive trigger is deferred to hormonal_contraceptive_effects. What follows is only enough mechanism to make the base-and-hierarchy intelligible.

Why visible light — not just UV — is the driver. Melasma pigment responds to short-wavelength visible light (the blue-violet end), not only to ultraviolet. Standard clear sunscreens are formulated to block UV and are largely transparent to visible light, so they leave the dominant trigger exposed. Iron oxides (the tint in a tinted sunscreen) absorb visible light, which is why a tinted / iron-oxide sunscreen protects where a clear one does not. This single distinction — visible-light coverage versus UV-only — is why the tinted arm beats the clear arm in trials and why "just wear SPF" is the wrong abstraction for melasma specifically.

Why the triggers are hormonal. Melasma is strongly associated with pregnancy ("the mask of pregnancy") and with combined oral contraceptives, implicating oestrogen/progesterone signalling in the overactivity of the pigment-producing cells. That hormonal substrate is why melasma is chronic-relapsing rather than a one-off insult, and why removing a hormonal trigger (where feasible and appropriate) can matter — but the endocrine detail belongs to hormonal_contraceptive_effects.

Why aggression rebounds. The pigment cells in melasma are primed and reactive; a high-energy laser delivers exactly the kind of inflammatory insult that drives post-inflammatory hyperpigmentation, so aggressive treatment can darken the target rather than clear it, especially in darker skin where the cells are more reactive. This is the mechanistic reason the procedural lever must be cautious and low-energy, not a first move.

Why photoprotection has to be the base. Because the driving stimulus (light, on a hormonal substrate) is continuous, any topical or procedure that lightens pigment is working against an ongoing trigger. Remove or blunt the trigger — with visible-light photoprotection — and the topicals have a stable base to work on and relapse slows. Leave the trigger uncovered and even a good topical is bailing against an open tap. That is why the verb is control, not cure: you are managing a reactive system with a persistent stimulus, not curing a one-time lesion.

Risks And Contraindications

• Do not present the working title as "no pill works." The claim "no supplement fixes it" is defensible for the OTC supplement / glutathione / detox market, but it must be stated carefully: low-dose ORAL tranexamic acid (a prescription anti-fibrinolytic, not a supplement) genuinely works. Conflating the two is a factual error and reads as anti-medication. Keep the distinction: no over-the-counter pill or supplement fixes melasma; one prescription systemic drug does, with caveats.
• Tranexamic acid carries thrombotic caveats that matter here specifically. It is contraindicated in people at thrombotic risk and interacts with the combined oral contraceptives that are themselves a melasma trigger. It belongs behind a clinician, never self-sourced. The hormonal trigger and the drug's interaction are two sides of the same coin.
• Hydroquinone is neither villain nor forever-cream. Present it honestly: an effective, well-supported topical used as a time-limited, supervised course, with a real misuse harm — exogenous ochronosis (paradoxical blue-black staining, hard to reverse) after prolonged, high-concentration, poorly-sun-protected use over years. Do not imply it is dangerous to use at all; do not imply it is safe to use forever.
• Availability differs by region. Hydroquinone is banned in over-the-counter cosmetics in the EU and restricted elsewhere; do not imply it is freely and safely available everywhere. Where it is restricted, azelaic acid is the proven alternative.
• Aggression rebounds — flag it as a harm, not just a disappointment. Aggressive or high-energy lasers can worsen and darken melasma, especially in Fitzpatrick IV to VI skin. Procedures must be cautious, low-energy and conservative. "Just laser it off" is an actively harmful pitch.
• Do not overstate the certainty of the photoprotection lever. The visible-light finding is well-supported mechanistically and by a few small, single-centre trials — not by a large body of evidence. It is the right base, but avoid claiming settled, large-trial certainty.
• Do not present the triple combination as durable remission. Its strongest evidence is short (8-week) and manufacturer-run, in a chronic-relapsing disease; frame it as short-term efficacy on a maintenance footing.
• Red-flag boundary — a changing or atypical pigmented lesion is not melasma to self-treat. Melasma is symmetrical facial pigmentation. A new, enlarging, irregular, asymmetric, multi-coloured or bleeding pigmented lesion — or any single spot that looks different from the rest — can be a skin cancer (including melanoma) and needs medical assessment, not a lightening cream. When in doubt about what a pigmented area is, see a clinician before treating it.

Controversy

Nature: a set of genuinely effective levers (visible-light photoprotection first, then hydroquinone / tretinoin / azelaic acid) entangled with a chronic-relapsing condition that is easily worsened and surrounded by an aggressive commercial market, with error at both poles — over-selling (a lightening pill or a laser will fix it) on one side, and over-restriction or fatalism (hydroquinone is poison / nothing works) on the other.

Position A — "The evidence-based levers genuinely work." The actionable take.
• Best evidence: real where it stays in the right order. Strict broad-spectrum photoprotection covering visible light (tinted / iron-oxide sunscreen) is the non-negotiable foundation, and on top of it hydroquinone, tretinoin, azelaic acid and the fixed triple combination have real RCT support for reducing MASI. Each holds under its stated condition.
• Where it goes wrong if overstated: it tips into "get the topicals right and you're cured," generalises the triple-combination's short-term win into durable remission, or reaches for aggressive lasers as a shortcut.

Position B — "Melasma is chronic-relapsing and easily worsened." The corrective take.
• Best evidence: correct on the ceiling and the harms. Aggressive lasers can rebound and darken the pigment; hydroquinone has real limits and a misuse harm (exogenous ochronosis after years of use); and the oral-supplement / glutathione / detox / IV-drip market is unsupported to weak. The honest verb is control, not cure.
• Where it goes wrong if overstated: it can slide into "hydroquinone is dangerous, avoid it" or "nothing works," which discards genuinely effective, well-supported topicals and the one systemic drug that helps — an over-correction that leaves people with only sunscreen.

The funding/bias dimension — cui bono, both ways. Toward over-selling: the skin-lightening industry (multi-billion-dollar, largely unregulated) profits from IV/oral glutathione, "detox" regimens and whitening supplements with no efficacy gate, and publication bias plus small industry-linked herbal trials inflate the supplement signal; laser and device clinics have a revenue incentive to push procedures despite the documented rebound risk; and much of the triple-combination (Tri-Luma) evidence base was funded by its manufacturer (Galderma), so its "gold standard" status rests partly on manufacturer-run 8-week trials. Toward the honest base: photoprotection and low-dose generic oral tranexamic acid are cheap, off-label or commodity — nobody markets them aggressively, so their real evidence is comparatively under-promoted relative to the hype.

Realised Position: Both positions are true and they compose into one rule. Photoprotection including visible-light coverage is the base without which every topical and procedure underperforms; the proven topicals (hydroquinone / tretinoin / azelaic acid / triple combination) are the adjuncts, used on a maintenance, control-not-cure footing; procedures are cautious-and-conservative because aggression rebounds; and the OTC supplement / detox market is noise. The one systemic exception is a prescription anti-fibrinolytic (oral tranexamic acid), NOT a supplement, and it carries thrombotic caveats that matter given melasma's hormonal (OCP/pregnancy) triggers. The loudest commercial voices — supplements and aggressive lasers — point away from the true foundation, which is exactly the inversion this entry corrects.

Cross-Pillar Connections

This is a genuinely cross-pillar topic — the base is a sun/light behaviour, the triggers are hormonal, and the failure modes are commercial.
• Cross-pillar (sunscreen_mineral_vs_chemical_and_sensible_sun): owns general sun behaviour and the mineral-versus-chemical sunscreen choice; this entry holds only the melasma-specific point that photoprotection must block visible light (tinted / iron-oxide), and defers sun behaviour there.
• Cross-pillar (artificial_light_vs_sunlight): owns the biology of visible versus ultraviolet light; this entry holds only that visible light drives melasma and hands the light physics there.
• Cross-pillar (evidence_based_minimal_skincare): owns general evidence-based skincare; this entry holds only the melasma-specific topical hierarchy and defers routine skincare there.
• Metabolic/Hormonal (hormonal_contraceptive_effects): owns the endocrinology of the combined oral contraceptive; this entry holds only that OCPs and pregnancy are melasma triggers, and that this hormonal trigger is exactly why oral tranexamic acid's OCP interaction matters.
• Evidence method (publication_bias_and_evidence_distortion): why the supplement / glutathione trials over-read positive — small, industry-linked, publication-bias-prone — and why the entry weights independent evidence over the market's.

What would change our mind

Industry bias note

Sources (9)

• Castanedo-Cazares JP, et al. (2014). Double-blind RCT of an iron-oxide tinted broad-spectrum sunscreen versus a UV-only sunscreen, each with 4% hydroquinone, in melasma. Photodermatol Photoimmunol Photomed. (Academic RCT, n=68.) — tinted arm ~15% greater MASI improvement than UV-only over 8 weeks; establishes visible light as a driver.↗
• Boukari F, et al. (2015). "Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light." J Am Acad Dermatol. (Prospective randomised comparative trial.) — UV + short-wavelength-visible-light sunscreen reduced relapse versus UV-only during high-sun periods; supports photoprotection as the maintenance base.↗
• Taylor SC, et al. (2003). "Efficacy and safety of a new triple-combination agent for the treatment of facial melasma." Cutis (pubmed.ncbi.nlm.nih.gov/12889718↗/" target="_blank" rel="noopener">PMID 12889718↗). (Two 8-week multicentre investigator-blind RCTs; manufacturer-funded — Tri-Luma / Galderma, FDA-approved 2002.) — ~77% reached a melasma severity score of 0 to 1 at week 8, beating each dual combination; short-term efficacy in a chronic-relapsing disease.
• Verallo-Rowell VM, et al. (1989). Double-blind trial of 20% azelaic acid versus 4% hydroquinone in melasma. Acta Derm Venereol Suppl (pubmed.ncbi.nlm.nih.gov/3073279↗/" target="_blank" rel="noopener">PMID 3073279↗); with Balina LM, Graupe K (1991), 24-week double-blind azelaic-acid trial, Int J Dermatol (pubmed.ncbi.nlm.nih.gov/1816137↗/" target="_blank" rel="noopener">PMID 1816137↗), n=329. (Academic blinded comparative RCTs.) — azelaic acid 20% broadly comparable to hydroquinone 4% (HQ faster); ~65% good/excellent results over 24 weeks. A proven non-HQ option, including where HQ is avoided (pregnancy).
• Exogenous ochronosis case-series / review literature — e.g. Charlin R, et al. Int J Dermatol 2008 (a four-case report) and skin-of-colour case characterisations of ochronosis after prolonged use; classic review Levin CY, Maibach HI (2001). (Case-series and pharmacovigilance, not RCT — the honest harm anchor.) — prolonged, high-concentration, poorly-sun-protected hydroquinone use risks paradoxical blue-black ochronosis, concentrated on cheeks/forehead/temples; the reason HQ is a time-limited course.↗
• Low-fluence Q-switched Nd:YAG for melasma: a systematic review (PMC9323185). (Systematic review of heterogeneous, often uncontrolled laser studies.) — documents recurrence/rebound and inflammation-driven worsening, especially in darker skin; supports cautious, low-energy, conservative procedural use only.↗
• Sarkar R, et al. (2025). "Glutathione as a skin-lightening agent and in melasma: a systematic review." Int J Dermatol; with a herbal-adjunct RCT meta-analysis (PMC8668325). (Reviews explicitly grade evidence weak/low-quality; publication-bias-prone. The skin-lightening supplement market is multi-billion-dollar and largely unregulated — cui bono favours over-claiming.) — oral glutathione and herbal/oral adjuncts (incl. Polypodium leucotomos) are weak-to-incomplete evidence with at most a modest adjunct effect; no basis for a stand-alone lightening pill.↗
• Feng X, et al. (2021). Updated meta-analysis of RCTs of oral tranexamic acid in melasma, J Clin Pharm Ther; with Bala HR, et al. (2018), "Oral Tranexamic Acid for the Treatment of Melasma: A Review," Dermatologic Surgery 2018;44(6):814-825; typical dose 250 mg twice daily. (Multiple RCTs + meta-analyses; off-label cheap generic — little commercial push.) — low-dose oral tranexamic acid (a prescription anti-fibrinolytic, not a supplement) reduces melasma; no thromboembolic events reported at these doses, but contraindicated in thrombotic risk and interacting with the OCPs that trigger melasma.↗
• Funding notation: the honest anchors (visible-light photoprotection; low-dose generic oral tranexamic acid) are cheap, commodity or off-label and comparatively under-promoted. The most commercially-motivated claims — the oral/IV glutathione and "detox" supplement market, and the aggressive-laser pitch — are the ones the entry classes as unsupported or cautions against. The best topical (the triple combination) is partly manufacturer-funded, which is why the entry frames its short-term win as maintenance, not cure.*↗

Related entries